PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

Overview of attention for article published in New England Journal of Medicine, June 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news: 73 news outlets
blogs: 4 blogs
policy: 1 policy source
twitter: 311 X users
patent: 31 patents
facebook: 7 Facebook pages

wikipedia: 1 Wikipedia page
googleplus: 1 Google+ user
reddit: 1 Redditor
f1000: 1 research highlight platform
guideline: 8 clinical guideline sources
podcasts: 2 podcasts

Readers on

mendeley: 952 Mendeley

So far, Altmetric has seen 352 X posts from 311 X users, with an upper bound of 1,891,566 followers.

@TargetedOnc @angelesclinic #PD1 #immunotherapy metastatic-disease response was observed 28/59 patients 47%; duration of response exceeded 6 months in 57%, and 82% continued to have a response.https://t.co/ElD3tWzOov

@TargetedOnc @angelesclinic There should not be a difference in this situation in relation to response rates. The toxicity profile is different and tolerable. Minimal data as the approval is in second line. PD1 as first line is a new option and furth…

Top read this week: The Immune System in Cutaneous Squamous Cell Carcinoma https://t.co/YjFcOArIn0 #immunotherapy #skincancer #cancer via @UniofOxford https://t.co/ssHLA3qM3F

RT @SirtSix: @XBIObserver Another modern classic image in clinical medicine: Anti-PD1 immunotherapy in advanced cutaneous squamous-cell ca…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 348 additional X posts.